AROG Pharmaceuticals

AROG Pharmaceuticals is a late-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing crenolanib for indications with high unmet needs. Crenolanib is an oral, potent, and selective, anti-mutant pan-FLT3 inhibitor. To date, crenolanib has been evaluated in more than 400 patients across 19 completed or ongoing clinical trials.